Tenaya Therapeutics, Inc.
HealthcareNASDAQ:TNYA · NASDAQ Global Select
-$0.01 today
Vol 1.38M · Avg 4.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-73.5%
avg -46.8%
ROIC
-69.4%
avg -63.8%
ROA
-61.7%
avg -55.4%
Analysis
ROA is currently the strongest return metric at -61.7% versus its period average of -55.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Faraz Ali | Chief Executive Officer, Interim Principal Financial Officer & Director | $983,964.00 | — | 53 | $440,014.00 | 0.26% |
Whittemore G. Tingley | Chief Medical Officer | $702,844.00 | — | 58 | $215,497.00 | 0.13% |
Deepak Srivastava | Scientific Founder, Chairman of Scientific Advisory Board & Director | $90,500.00 | — | 59 | $120,000.00 | 0.07% |
Benoit G. Bruneau | Scientific Founder | — | — | — | — | — |
Bruce R. Conklin | Scientific Founder | — | — | — | — | — |
Saptarsi Haldar | Scientific Founder | — | — | — | — | — |
Sheng Ding | Scientific Founder | — | — | — | — | — |
Eric N. Olson | Scientific Founder & Member of Scientific Advisory Board | — | — | — | — | — |
Kee-Hong Kim | Chief Technology Officer | — | — | 60 | — | — |
Tomohiro Higa | Senior Vice President of Finance & Interim Principal Accounting Officer | — | — | 57 | $118,267.00 | 0.07% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
35
$5.06M
Net Sentiment
$5.06M
Net selling
Most Active
COLUMN GROUP III GP, LP
11 transactions
1–10 of 35
Analysis
Insiders reported 0 buys worth $0.00 and 35 sells worth $5.06M over the last 12 months. That adds up to net selling of $5.06M. COLUMN GROUP III GP, LP was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Abeona Therapeutics Inc.
NASDAQ:ABEO
$315.18M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Who manages TNYA?
Tenaya Therapeutics, Inc. (TNYA) lists 10 active executives. The top listed executive is Faraz Ali, Chief Executive Officer, Interim Principal Financial Officer & Director.
Are TNYA insiders buying or selling?
Recent insider activity shows net buying of $230.48M.
Explore More
Continue the stock analysis
Jump to another research area for this company.